Form 8-K dated December 4, 2002
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 4, 2002
Targeted Genetics Corporation
(Exact name of registrant as specified in charter)
| Washington |
|
0-23930 |
|
91-1549568 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| 1100 Olive Way, Suite 100, Seattle, Washington |
|
98101 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (206) 623-7612
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events.
On December 4, 2002, Targeted Genetics Corporation announced it has received notification from Celltech Group plc of its decision to
terminate a collaborative agreement between the companies in support of Targeted Genetics’ cystic fibrosis program. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.
Item 7. Exhibits.
| |
(a) |
|
Financial statements of business acquired. |
Not applicable.
| |
(b) |
|
Pro forma financial information. |
Not applicable.
| Exhibit No.
|
|
Description
|
| 99.1 |
|
Press Release dated December 4, 2002 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
|
|
TARGETED GENETICS CORPORATION |
| |
| Date: December 4, 2002 |
|
|
|
By: |
|
/s/ TODD E. SIMPSON
|
| |
|
|
|
|
|
|
|
Vice President, Finance and Administration and Chief Financial Officer, Secretary and Treasurer (Principal Financial and Accounting
Officer) |
3
EXHIBIT INDEX
| Exhibit No.
|
|
Description
|
| 99.1 |
|
Press Release dated December 4, 2002 |